AZD-1080 CITRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H18N4O2.C6H8O7
Molecular Weight	526.4953
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.OC1=C(C2=C(N1)C=CC(=C2)C#N)C3=CC=C(CN4CCOCC4)C=N3

InChI

InChIKey=QIXMKFAORYGAFN-UHFFFAOYSA-N

InChI=1S/C19H18N4O2.C6H8O7/c20-10-13-1-3-16-15(9-13)18(19(24)22-16)17-4-2-14(11-21-17)12-23-5-7-25-8-6-23;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-4,9,11,22,24H,5-8,12H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23410232 | https://www.ncbi.nlm.nih.gov/pubmed/27051274 | https://www.ncbi.nlm.nih.gov/pubmed/27050373

AZ-1080 (AZD-1080) is an inhibitor of GSK-beta which was developed by AstraZeneca and initially tested in patients with Alzheimer’s disease (phase I). The drug was discontinued for the aforementioned condition, but now it is being investigated as a potential therapy for ovarina cancer and emdometrial carcinoma (basic research).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glycogen synthase kinase-3 beta 52 Target ID: CHEMBL262 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23410232	Inhibitor 8504		31.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Alzheimer’s disease 278 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23410232	Primary	Phase I 438	Unknown Approved Use Unknown
Ovarian cancer 160 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27051274	Primary	Basic research	Unknown Approved Use Unknown
Endometrial cancer 44 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27050373	Primary	Basic research	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
86 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23410232	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AZD-1080 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23410232	15 mg 1 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		AZD-1080 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
15 mg 1 times / day steady-state, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: steady-state Dose: 15 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23410232	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/23410232	Sources: https://pubmed.ncbi.nlm.nih.gov/23410232

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741

Drug as perpetrator

Target	Modality	Activity
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363680184	inconclusive [IC50 29.0929 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=363680752	yes [IC50 16.933 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=363680752	yes [IC50 6.0081 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645841#sid=363680752	yes [IC50 6.7412 uM]

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P003EV6	https://www.1pchem.com/search?query=1P003EV6
AChemBlock	M15675	http://www.achemblock.com/catalogsearch/result/?q=M15675
AK Scientific	X6996	https://aksci.com/item_detail.php?cat=X6996
Ambeed	A166126	http://www.ambeed.com/search/Search.html?keyword=A166126
Angene	AGN-PC-0SZJUP	http://www.angenechemical.com/productshow/AGN-PC-0SZJUP.html
AOBIOUS INC	AOB87345	http://aobious.com/aobious/search?search_query=AOB87345
AstaTech	F17385	http://astatechinc.com/CPSResult.php?CRNO=F17385
Axon MedChem	2171	https://www.axonmedchem.com/product/2171
BLD Pharm	BD328422	http://www.bldpharm.com/search/Search.html?keyword=BD328422
Cayman Chemical	16676	http://www.caymanchem.com/app/template/Product.vm/catalog/16676
ChemShuttle	110107	https://www.chemshuttle.com/catalogsearch/result/?q=110107
Combi-Blocks	QW-5453	http://www.combi-blocks.com/cgi-bin/find.cgi?QW-5453
eMolecules	48544545	https://orderbb.emolecules.com/search/#?query=48544545
eNovation Chemicals	D372289	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D372289&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A230	http://www.excenen.com/searchresultlist.php?id=EX-A230
KeyOrganics	AS-55896	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-55896
Lab Network	LN01274605	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01274605
Matrix Scientific	146803	http://www.matrixscientific.com/146803.html
MedChem Express	HY-13862	https://www.medchemexpress.com/search.html?q=HY-13862&ft=&fa=&fp=
MolPort	MolPort-028-754-155	https://www.molport.com/shop/molecule-link/MolPort-028-754-155
MuseChem	I004307	https://www.musechem.com/product/I004307.html
Ryan Scientific	101-94140	https://ryansci.com/products?q=101-94140&list_q=&search_type=exact
Selleck Chemicals	S7145	http://www.selleckchem.com/search.html?searchDTO.searchParam=S7145
ShangHai Biochempartner	BCP000938	http://www.biochempartner.com/search_BCP000938
ShangHai Biochempartner	BCP07919	http://www.biochempartner.com/search_BCP07919
Toronto Research Chemicals	A808085	https://www.trc-canada.com/product-detail/?CatNum=A808085

PubMed

Title	Date	PubMed
The role of glycogen synthase kinase-3β (GSK-3β) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker.	2016-05-10	27050373
Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer.	2016	27051274
Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system.	2013-10	23793101
AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.	2013-05	23410232

Patents

Sample Use Guides

In Vivo Use Guide

Middle-aged subjects (45–64 years) receive 15 mg AZ-1080 once daily for 14 days.

Route of Administration: Oral

In Vitro Use Guide

3T3 ﬁbroblasts stably expressing human tau protein were treated with 1 uM of AZ-1080. Dose-dependent inhibition of tau phosphorylation was observed for AZ-1080 with IC50 value of 324 nM.

Name

Type

Language

AZD1080 CITRATE

Preferred Name

English

AZD-1080 CITRATE

Code

English

2-Hydroxy-3-[5-[(morpholin-4-yl)methyl]pyridin-2-yl]-1H-indole-5-carbonitrile citrate

Systematic Name

English

1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylmethyl)-2-pyridinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

Common Name

English

Code System Code Type Description

FDA UNII

Y2785L6ZLV

Created by admin on Wed Apr 02 19:34:31 GMT 2025 , Edited by admin on Wed Apr 02 19:34:31 GMT 2025

PRIMARY

PUBCHEM

135802773

Created by admin on Wed Apr 02 19:34:31 GMT 2025 , Edited by admin on Wed Apr 02 19:34:31 GMT 2025

PRIMARY

CAS

945633-71-6

Created by admin on Wed Apr 02 19:34:31 GMT 2025 , Edited by admin on Wed Apr 02 19:34:31 GMT 2025

PRIMARY

ACTIVE MOIETY


					0TII45R8IJ

AZD-1080

SUBSTANCE RECORD


					Y2785L6ZLV

AZD-1080 CITRATE

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23410232 | https://www.ncbi.nlm.nih.gov/pubmed/27051274 | https://www.ncbi.nlm.nih.gov/pubmed/27050373

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Cmax

T1/2

Doses

Overview

OverviewOther

Drug as perpetrator​

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23410232 | https://www.ncbi.nlm.nih.gov/pubmed/27051274 | https://www.ncbi.nlm.nih.gov/pubmed/27050373

C_max

T_1/2

Drug as perpetrator